



**The Canadian Association for Population Therapeutics /
Association Canadienne pour la Thérapeutique des Populations
Presents:**

**“Drivers of Change: How HTA, Evidence and Policy Affect
Perceptions of Value and Health Care Practice”**

PROGRAM

November 2nd – 4th, 2014

Toronto, Ontario

**DoubleTree by Hilton
108 Chestnut Street
Toronto, Ontario**

CAPT-ACTP MISSION & VISION

The CAPT-ACTP Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT-ACTP Vision is to be the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

CAPT-ACTP 2014 BOARD OF DIRECTORS:

Allan Gillman	CAPT-ACTP President, IMS Brogan Inc.;
Nicole Mittmann	CAPT-ACTP Past President, HOPE Research Centre, Sunnybrook Research Institute, University of Toronto;
Valencia Remple	CAPT-ACTP President Elect, Abbvie Corporation, University of British Columbia;
Peggy Kee	CAPT-ACTP Administrator, HOPE Research Centre, Sunnybrook Research Institute;
Suzanne Cadarette	Leslie Dan Faculty of Pharmacy, University of Toronto;
Brian Chan (student)	Leslie Dan Faculty of Pharmacy, University of Toronto;
Mary De Vera	Faculty of Pharmaceutical Sciences, University of British Columbia;
Peter Dyrda	Janssen Inc.;
Dean Eurich	School of Public Health, University of Alberta;
Kirsten Garces	AMGEN Canada Inc.;
Naeem Ladhani	Alberta Health Services;
Colleen J Metge	Winnipeg Regional Health Authority;
Louise Perrault	International Market Access Consulting;
Laurene Redding	Takeda Canada Inc.;
Soo Jin Seung	HOPE Research Centre, Sunnybrook Research Institute;
Melissa Thompson	Cornerstone Research Group.

CAPT-ACTP 2014 SCIENTIFIC PROGRAM COMMITTEE:

Chairs:	Valencia Remple and Dean Eurich
Members:	Suzanne Cadarette Mary De Vera Kirsten Garces

CAPT-ACTP 2014 LOCAL ORGANIZING COMMITTEE:

Chair:	Soo Jin Seung
Members:	Allan Gillman Peggy Kee

CAPT-ACTP 2014 MEMBERSHIP COMMITTEE:

Chairs:	Naeem Ladhani and Peter Dyrda
---------	-------------------------------

CAPT-ACTP 2014 PARTNERSHIP COMMITTEE:

Chairs:	Melissa Thompson and Nicole Mittmann
Members:	Laurene Redding Angela Rocchi

CAPT-ACTP 2014 STUDENT COMMITTEE:

Chairs:	Suzanne Cadarette and Brian Chan
---------	----------------------------------

CAPT-ACTP 2014 FINANCE COMMITTEE:

Chair:	Colleen Metge
--------	---------------

“Drivers of Change: How HTA, Evidence and Policy Affect Perceptions of Value and Health Care Practice”

Message from the President

It is my pleasure to welcome you to the 2014 Canadian Association for Population Therapeutics (CAPT)/ Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! If you are new to CAPT-ACTP, we know you will enjoy our intimate and collegial conference that is unique in bringing together the perspectives of academia, industry, and government (and increasingly private payers). To those of you who are returning, we know you will once again be engaged by the program that our Scientific Program Committee has pulled together for this year!

The theme of this year’s conference *“Drivers of Change: How HTA, Evidence and Policy Affect Perceptions of Value and Health Care Practice”* allows us to explore the many ways in which public health policy, HTA, and the impact of the environment is being felt in health care practice. This has allowed us to examine topics as varied as influenza vaccinations, changes impacting pharmacy and allied health professionals, outcomes based PLAs, what “best” is in HTA, the CADTH-DSEN partnership, and much, much more!

We also have a full slate of panels, presentations, posters, and workshops for you to enjoy, and many opportunities to engage with others participating in the conference. We are particularly proud of our support of student engagement at the conference in oral presentations, posters, networking and social events. We hope you participate as much as you can!

The Scientific Program Committee, the Local Organizing Committee, and our Partnership Committee have done an incredible job in making sure that everything comes together in what you’ll see over the duration of the conference. I want to thank them, our speakers, participants, and partners for contributing to our ongoing success. Please let us know what we can do better, spread the word, and consider becoming more actively involved! Most of all...enjoy!

Allan F. Gillman
CAPT-ACTP President

CAPT-ACTP 2014 Conference Overview

We are pleased to welcome you to the 2014 CAPT-ACTP conference. The title of this year's conference, "*Drivers of Change: How HTA, Evidence and Policy Affect Perceptions of Value and Health Care Practice*", speaks to the dynamic nature of the Canadian health care environment and the continued need to demonstrate value in an environment of constrained resources.

CAPT's mission is to bring together stakeholders from diverse perspectives for scientific and policy exchange, and to dialogue on hot topics in health care practice. This year's meeting continues to draw on the collective wisdom of all our constituencies, including academia, industry, government and trainees. Given our pre-conference workshop/symposium, panel discussions, abstract presentations and ongoing collaboration with CIHR/DSEN/CNODES, the 2014 CAPT-ACTP meeting promises to have something for everyone!

The Scientific Program Committee acknowledges and thanks the many partners who have made the size and scope of this year's conference possible. Their investment in CAPT-ACTP, combined with our talented pool of members, makes it all possible. We hope you enjoy the conference!

Dean Eurich and Valencia Remple
CAPT-ACTP Scientific Program Committee Chairs

“Drivers of Change: How HTA, Evidence and Policy Affect Perceptions of Value and Health Care Practice”

Sunday, November 2, 2014

07:15 – 17:00 **Registration**
Location: Mandarin Ballroom Foyer

Pre-Conference Activities

08:00 – 12:00 **Pre-conference workshop: Understanding burden of illness using RWE: building patient cohorts for quick and accurate patient insights from EMR in Canada (organized by IMS Brogan Inc.)**
Location: Mandarin Ballroom
Facilitator: Richard Borrelli, IMS Brogan Inc.;
Presenters: Khaled El Emam, Privacy Analytics & Canada Research Chair in Electronic Health Information, University of Ottawa;
Thom Tyson, Canadian Health Systems Inc. and Appletree Medical Group.

- Real World Evidence has become an important tool in the toolkit of companies dealing with public and private payers and HTA bodies. Focusing on delivering burden of illness and providing insights to the value of medicine electronic medical records have become a gold mine of information for the researcher wishing to deliver these insights.
- What makes a good system? Relevant data, which is structured and contained in electronic format and linked; prescriptions, diagnoses, lab results, referrals and vital signs. This data needs to be rigorously de-identified to mitigate the risk of re-identifying a patient, structured in a way that a researcher can interrogate the data using a simple tool to enable the analysis of the data and the production of a study.
- IMS Brogan will demonstrate the first tool of this kind available in Canada along with a validated data set for undertaking research into the use of pharmaceuticals in the primary care setting.

Conference Commencement

- 13:00 – 13:10** **Welcome introduction to the conference**
Location: Mandarin Ballroom
Presenter: Allan Gillman, IMS Brogan Inc. and President, CAPT-ACTP.
- 13:15 – 14:00** **Do flu shots really work?**
Location: Mandarin Ballroom
Chair: Dean Eurich, School of Public Health, University of Alberta;
Speaker: Jeffrey Kwong, Department of Family & Community Medicine;
Dalla Lana School of Public Health, University of Toronto.
- 14:00 – 15:00** **Stakeholders panel discussion - vaccines and policy in Canada**
Location: Mandarin Ballroom
Moderator: Dean Eurich, School of Public Health, University of Alberta;
Panelists: John Spika, Centre for Immunization and Respiratory Infectious
Disease, Public Health Agency;
Jeffrey Kwong, Department of Family & Community Medicine;
Dalla Lana School of Public Health, University of Toronto;
Lorraine LeBlanc, Patient/Public Health Advocate, Ontario;
Wilson Li, Shoppers Drug Mart, Toronto;
Alison Thompson, University of Toronto.
- 15:00 – 15:30** **Break** **(Sponsor: AMGEN Canada Inc.)**
- 15:30 – 16:15** **Issues in subsequent entry biologics in Canada**
Location: Mandarin Ballroom
Chair: Kirsten Garces, AMGEN Canada Inc.
Speaker: Deborah Marshall, University of Calgary, Alberta Bone & Joint
Health Institute.
- 16:15 – 17:15** **Contributed elevator presentations: “Why you should view this year’s
posters!”**
Location: Mandarin Ballroom
Chair: Dean Eurich, School of Public Health, University of Alberta;
Speakers: Presenting authors of 15 top ranked posters.
- 17:15 – 17:30** **Day 1 summary comments**
Location: Mandarin Ballroom
Presenter: Allan Gillman, IMS Brogan Inc. and President, CAPT-ACTP.
- 17:30 – 18:30** **Contributed poster presentations session #1 and reception
(Sponsor: AstraZeneca Canada Inc.)**
Location: Ottawa Room

18:30 – 19:30

Student mentoring session (open to CAPT-ACTP student registrants only)

Location: Mandarin Ballroom

Chair: Brian Chan, Leslie Dan Faculty of Pharmacy, University of Toronto
and Student Committee Member CAPT-ACTP.

19:30

Student social event (open to CAPT-ACTP student registrants only)

Monday, November 3, 2014

- 07:30 – 17:00** **Registration**
Location: Mandarin Ballroom Foyer
- 08:00 – 08:45** **Breakfast (Sponsor: GlaxoSmithKline Inc.)**
Location: Mandarin Ballroom Foyer
- 08:45 – 9:00** **Welcome to Day 2**
Location: Mandarin Ballroom
Presenter: Allan Gillman, IMS Brogan Inc. and President, CAPT-ACTP
- 09:00 – 10:30** **Panel session: Targeting innovative outcomes-based product listing agreements in Canada: taking PCPA to the next level (Sponsor: Janssen Inc.)**
Location: Mandarin Ballroom
Chair: Chris Henshall, Brunel University, United Kingdom;
Speakers: Michael Drummond, Centre for Health Economics, University of York, United Kingdom;
Melissa Thompson, Cornerstone Research Inc;
Julia Brown, Janssen Inc.;
Brad Alyward, Nova Scotia Department of Health & Wellness.
- 10:30 – 11:00** **Break**
- 11:00 – 12:00** **The private payer landscape: what does the data tell us and what are the promising solutions?**
Location: Mandarin Ballroom
Chair: Mary De Vera, Faculty of Pharmaceutical Sciences, University of British Columbia;
Speakers: David Willows, Strategic Market Solutions, Green Shield Canada;
Susanne Cookson, Cookson James Loyalty.
- 12:00 – 13:30** **Lunch & annual general meeting (Sponsor: Gilead Sciences Canada Inc.)**
Location: Mandarin Ballroom
- 13:30 – 14:15** **Keynote address: New frontiers for pharmacy services across Canada: challenges and opportunities**
Location: Mandarin Ballroom
Chair: Dean Eurich, School of Public Health, University of Alberta;
Speaker: Lisa Dolovich, McMaster University.

14:15 – 14:45 **Remuneration of allied health professionals – a changing landscape**
Location: Mandarin Ballroom
Chair: Dean Eurich, School of Public Health, University of Alberta;
Speaker: Michele Evans, Alberta Ministry of Health.

14:45 – 15:15 **Break**

15:15 – 16:45 **Contributed oral presentations – concurrent sessions**

Concurrent session 1

Location: Mandarin Ballroom A
Chair: Mary De Vera, Faculty of Pharmaceutical Sciences, University of
British Columbia.

1. Impact of country-specific EQ-5D tariffs.

Kelly Lien

2. A population based cross-sectional study of comparison of breast cancer stage at diagnosis between immigrant women and general population in Ontario.

Javaid Iqbal

3. Chronic diabetic ulcers of the lower limb: results from a double-blind, randomized controlled trial comparing wound care with adjunctive hyperbaric oxygen therapy to wound care alone.

Daria O'Reilly

4. Anticholinergic drug burden in persons with dementia: The effect of multiple prescribers.

Christina Reppas-Rindlisbacher

5. Health utility estimates of Canadian cancer patients.

Hiten Naik

6. Medication co-payment for seniors impacts prevalent but not incident users of chronic medications.

Shenzhen Yao

Concurrent session 2

Location: Mandarin Ballroom B

Chair: Suzanne Cadarette

1. Prescription stimulant use and hospitalization for psychosis: a population-based case-crossover study.

Alex Cressman

2. The efficacy and safety of electronic nicotine delivery devices (e-cigarettes) as a method for smoking cessation: a systematic review and meta-analysis.

Shoghag Khoudigian

3. Retrospective evaluation of drug therapy recommendations made by pharmacists providing pharmaceutical opinion service in Ontario.

Nedzad Pojskic

4. Economic evaluation of sofosbuvir in hepatitis C: a Canadian perspective.

Angela Rocchi

5. A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip System in high surgical risk patients with significant mitral regurgitation.

Heather Cameron

6. A descriptive analysis of the Ontario MedsCheck annual pharmacy medication review service.

Giulia Consigilo

16:45 – 17:00

Day 2 Summary

Chairs: Allan Gillman, Mandarin Ballroom A;
Suzanne Cadarette, Mandarin Ballroom B.

17:00 – 18:00

**Contributed poster presentations session #2 and reception
(Sponsor: AstraZeneca Canada Inc.)**

Location: Ottawa Room

Tuesday, November 4, 2014

- 07:30 – 13:00** **Registration**
Location: Mandarin Ballroom Foyer
- 07:45 – 08:30** **Breakfast** **(Sponsor: IMS Brogan Inc.)**
Location: Mandarin Ballroom Foyer
- 08:30 – 08:45** **Welcome to Day 3**
Location: Mandarin Ballroom
Presenter: Allan Gillman, IMS Brogan Inc. and President, CAPT-ACTP.
- 08:45 – 10:15** **Panel session: What ‘BEST’ looks like in Canada for HTA (Sponsor: Pfizer Canada Inc.)**
Location: Mandarin Ballroom
Chair: Michael Drummond, Centre for Health Economics, University of York, United Kingdom;
Speakers: Jeffrey Hoch, St. Michael’s Hospital;
 Matthew Brougham, Independent Consultant;
 Fiona Miller, Institute of Health Policy, Management and Evaluation, University of Toronto.
- 10:15 – 10:45** **Break**
- 10:45 – 12:15** **DSEN’s research supporting decision-making and HTA (Sponsor: CIHR/ CNODES/ DSEN)**
Location: Mandarin Ballroom
Chair: Diane Forbes, Drug Safety and Effectiveness Network (DSEN);
Presenters: Sirjana Pant, CADTH – A collaborative approach to evidence informed policy-making – The CADTH-DSEN partnership;
 Michael Paterson, CNODES – Trends in Opioid Prescribing since the introduction of OxyNEO;
 Sasha Bernatsky, CAN-AIM – Fractures and SSRIs;
 Andrea Tricco, MAGIC – The DSEN query experience with insulin glargine.
- 12:15 – 13:15** **Lunch** **(Sponsor: Takeda Canada Inc.)**
Location: Mandarin Ballroom

13:15 – 14:45

Panel session: pCODR version 2.0: Moving forward

Location: Mandarin Ballroom

Chair: Jeffrey Hoch, St. Michael's Hospital

Panelists: Max Coppes, British Columbia Cancer Agency;
Mona Sabharwal, pan Canadian Oncology Drug Review;
Carole McMahon, pan Canadian Oncology Drug Review;
Farzad Ali, Pfizer Canada Inc.;
Kelvin Chan, Odette Cancer Centre, Sunnybrook Hospital.

14:45 – 15:15

CAPT-ACTP Awards Ceremony / Conference Close

Location: Mandarin Ballroom

Presenter: Allan Gillman, IMS Brogan Inc. and CAPT-ACTP President.

For any inquiries (abstracts, hotel, registration, etc.), please contact Ms. Peggy Kee (peggy.kee@sunnybrook.ca) or visit the CAPT-ACTP website (www.capt-actp.com).

ORAL PRESENTATIONS

(Note: Presenting authors are underlined)

1

Lien K, Tam VC, Ko Y-J, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KKW. **Impact of country-specific EQ-5D tariffs.**

2

Iqbal J, Narod S, Anderson G, Ginsburg O, Fischer H, Fung K, Creatore M, Austin P, Rochon P. **A population based cross-sectional study of comparison of breast cancer stage at diagnosis between immigrant women and general population in Ontario.**

3

O'Reilly D, Fedorko L, Giffening W, Nunes E, MacDougald C, Hopkins R, Bowen J, Goeree R. **Chronic diabetic ulcers of the lower limb: results from a double-blind, randomized controlled trial comparing wound care with adjunctive hyperbaric oxygen therapy to wound care alone.**

4

Reppas-Rindlisbacher C, Gill S, Seitz D, Tannenbaum C, Fischer H, Fung K, Austin P, Rochon P. **Anticholinergic drug burden in persons with dementia: the effect of multiple prescribers.**

5

Naik H, Qiu X, Brown MC, Pringle D, Eng L, Mahler M, Hon H, Tiessen K, Ho V, Thai H, Gonos C, Pat V, Irwin M, Charow R, Herzog L, Ho A, Xu W, Howell D. **Health utility estimates of Canadian cancer patients.**

6

Yao SZ, Lix L, Teare G, Shevchuk Y, Champagne A, Blackburn D. **Medication co-payment for seniors impacts prevalent but not incident users of chronic medications.**

7

Cressman AM, Macdonald EM, Huang A, Gomes T, Paterson JM, Kurdyak PA, Mamdani MM, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). **Prescription stimulant use and hospitalization for psychosis: a population-based case-crossover study.**

8

Khoudigian S, Devji T, Lytvyn L, Campbell K, Hopkins R, O'Reilly D. **The efficacy and safety of electronic nicotine delivery devices (E-cigarettes) as a method for smoking cessation: a systematic review and meta-analysis.**

9

Pojiskic N, Dolovich L. **Retrospective evaluation of drug therapy recommendations made by pharmacists providing pharmaceutical opinion service in Ontario.**

10

Rocchi A, Rogers T, Guerra I, Cure S. **Economic evaluation of sofosbuvir in hepatitis C: a Canadian perspective.**

11

Cameron HL, Bernard LM, Asgar AW. **A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip System in high surgical risk patients with significant mitral regurgitation.**

12

Dolovich L, Consiglio GP, Abrahamyan L, Bojarski E, MacKeigan L, Pechlivanoglou P, Pojskic N, Rac VE, Su J, Krahn M, Cadarette SM. **A descriptive analysis of the Ontario MedsCheck Annual pharmacy medication review service.**

13

Moura CS, Levesque LE, Daskalopoulou SS, Bernatsky S, Abrahamowicz M, Avgil Tsadok M, Rajabi S, Pilote L. **Hypertension treatment and cross-sectional relationship with peripheral and central blood pressure in non-diabetic participants from the CARTaGENE Cohort Study.**

14

Hu J, Cury F, Aprikian A, Faria S, Souhami L, Duclos M, Dragomir A. **Hypofractionation versus conventionally fractionated radiotherapy for low-intermediate risk prostate cancer: clinical and economic evaluation.**

15

Tadrous M, Mamdani MM, Juurlink DN, Lévesque LE, Krahn MD, Cadarette SM. **Performance of the Disease Risk Score (DRS) in a cohort with policy induced selection bias.**

16

Chabot I, Rocchi A. **Oncology drug HTA recommendations: Canadian versus UK experiences.**

17

Guertin JR, Rahme E, LeLorier J. **Use of multiple exposure measures in order to examine the potential mechanism of action by which statins could cause diabetes.**

18

Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A. **Clinical management and burden of prostate cancer: a Markov Monte Carlo Model.**

19

Wong WWL, Tu H-A, Feld J, Wong T, Krahn M. **Cost-effectiveness of screening hepatitis C in Canada.**

20

Mittmann N, Porter J, Rangrej J, Seung SJ, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau M, Evans WK, Dainty KN, DeAngelis C, Earle CC. **First two years of health system resources and costs following a stage defined breast cancer diagnosis: a population based approach.**

21

Naik H, Qiu X, Brown MC, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Charow R, Gonos C, Irwin M, Pat V, Herzog L, Eng L, Pringle D, Ho A, Xu W, Howell D. **Feasibility of routinely administrating the EQ-5D health utility instrument to cancer patients.**

22

Cressman AM, Macdonald EM, Yao Z, Austin PC, Gomes T, Paterson JM, Kapral MK, Mamdani MM, Juurlink DN for the Canadian Drug Safety and Effectiveness Research Network. **Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: a population-based study.**

23

Hong C, Kim S, Troyan S, Keshavjee K, Holbrook A. **Order and good governance? Reporting on governance by research organizations.**

24

Kröger E, Tatar O, Molin P, Finken L, Tourigny A, Giguère A, Voyer P, Guénette L, Grégoire JP, Vedel I. **Which interventions may enhance medication adherence among seniors with cognitive impairment - a systematic literature review.**

25

Dragomir A, Kassouf W, Aprikian A, Jewett M, Kapoor A, Breau R, Rendon R, Lacombe L, Lattouf JB, Klotz L, Pautler S, Drachenberg D, Moore R, Black P, Tanguay S. **Estimate the clinical and economic impact of urologists' adherence to the follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma in Canada.**

26

Yin L, Younger S, Shum D. **Is oncology drug funding in Quebec different from the rest of Canada?**

27

Chan BC, Cadarette SM, Wodchis WP, Krahn MK, Mittmann N. **The health care cost of spinal cord injury in an Ontario cohort.**

POSTER PRESENTATIONS

Session 1: Sunday November 2, 2014

28

Millson B, Poulin-Costello M, Garces K. **Reimbursement patterns for Enbrel® (etanercept) as senior patients transition from private to public drug plan insurance.**

29

Kröger E, Wilchesky M, Arcand M, Aubin M, Champoux N, Durand P, Giguère A, Morin M, Voyer P, Verreault R. **Development of an educational tool for an interprofessional intervention to reduce medication load for long term care residents with advanced dementia: OPTIMAMED.**

30

Hollmann S, Alloul K, Attard C, Kavan P. **An indirect treatment comparison and cost-effectiveness analysis comparing FOLFIRINOX to nab-paclitaxel + gemcitabine for first-line treatment of patients with metastatic pancreatic cancer.**

31

Nehmé K, Wakeford C, Lachaine J. **The impact of the abolition of Quebec's innovative drug protection plan (BAP15).**

32

McAuley G, Chan W, Wong M. **Changes in opioid utilization and prescribing after delisting of long-acting oxycodone from a provincial drug plan.**

33

Tsao NW, Marra CA, Lynd LD, Gastonguay L, Nakagawa B. **Impact of expanded pharmacy services in British Columbia.**

34

Farahani P. **Gender gap for LDL-C goal attainment amongst patients with diabetes: a systematic review.**

35

Farahani P. **Challenges in pharmacotherapeutics education for diabetes in real-world clinical settings: views from family medicine and internal medicine residents.**

Session 2: Monday November 3, 2014

36

Attard CL, Pepper AN, Brown ST, Thompson MF, Thuresson PO, Yungler S, Dent S, Paterson AH, Wells GA. **Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2+ breast cancer in Canada.**

37

Aziz S, Gillman A, Wang T, Griffiths J. **Atomoxetine – utilization patterns in Canada.**

38

Gillman AF. **Using electronic medical records as real world evidence to understand the impact of flu vaccinations on patient health.**

39

Tsoi B, Huserreau D, O'Reilly D, Campbell K, Goeree R. **Harmonization of health technology assessment and regulatory approval: a bridge over the chasm.**

40

Church D, Waite NM, Schneider E. **Expanding pharmacists' immunization authority in Ontario: a jurisdictional and scoping review.**

41

Kellar J, Mittmann N, Von Heymann C, Zingaro J, Kuriakose B, Li A. **Costs of employees with treatment-resistant depression based on a Canadian private claims database.**

42

Tricco AC, Veroniki AA, Hamid JS, Straus SE. **Incorporating dosages increase the relevance of network meta-analysis for decision-makers: A case example using data from a systematic review of serotonin (5-HT3) receptor antagonists in patients undergoing surgery.**

43

Samjoo IA, Heyland KE, Grima DT. **Single-arm clinical trials and a lack of statistically significant overall survival are not an absolute barrier to a positive pCODR recommendation for an oncology product.**

44

Tran Y, Polk G, Ma J. **Measuring private payer changes: trends in market access restrictions using real world data.**

45

Samjoo IA, Grima DT. **Majority of oncology products receive a positive recommendation in Canada conditional on improved cost-effectiveness.**

46

Mitton C, Dionne F, Gibson J, Lynd L, Dempster W. **Value of pharmaceuticals- a multi-criteria approach.**

47

Yao SZ, Lix L, Teare G, Shevchuk Y, Champagne A, Blackburn D. **Impact of a provincial drug plan policy limiting out-of-pocket payment for seniors: a population-based study in Saskatchewan, Canada.**

48

Shustik J, Tay J, Hollmann S, LeBlanc R. **A Canadian cost impact analysis comparing maintenance therapy with bortezomib versus lenalidomide in multiple myeloma patients ineligible for stem cell transplant.**

49

LeBlanc R, Tay J, Hollmann S, Shustik J. **A Canadian cost analysis comparing the use of bortezomib or lenalidomide as maintenance therapies in multiple myeloma patients eligible for autologous stem cell transplant.**

50

Mittmann N, Hassan S, Seung SJ, Bannon G, Cheung M, Fraser G, Kuriakose B. **Health care resource utilization in the management of chronic lymphocytic leukemia at an Ontario cancer centre.**

51

Friesen KJ, Bugden SC. **Voluntary warnings and the limits of good prescribing behaviour: the case for de-adoption of meperidine (Demerol®).**

52

Levine M. **NNTnet: A metric for evaluating relative harms and benefits.**

53

Mittmann N, Hassan S, Patel J, Tinmouth J. **Cost-effectiveness of directly mailed FOBT kits in a hard to reach population in colorectal cancer screening.**

54

Hux M, Li C, Risebrough N, Goeree R, Sculpher M, Kapur A, Briggs A. **Coverage with evidence development: opportunities for improving access to new technologies in the Canadian environment.**



2014 CAPT-ACTP CONFERENCE PARTNERS

DIAMOND

CIHR / DSEN / CNODES

Janssen Inc.

Pfizer Canada Inc.

PLATINIUM

AstraZeneca Canada Inc.

GOLD

Amgen Canada Inc.

Gilead Sciences Canada Inc.

GlaxoSmithKline Inc.

IMS Brogan Inc.

Takeda Canada Inc.

SILVER

Athena Research

Cornerstone-Research Group

Hoffmann-La Roche Ltd.

Intermune Canada Inc.

Mapol Inc.

Purdue Pharma

BRONZE

Axone Market Access Consulting Inc.

HOPE Research Centre

Kotylak Consulting

We gratefully acknowledge sponsorship of the 2014 CAPT-ACTP Conference by the following partners:



DIAMOND



PLATINUM



GOLD



SILVER



BRONZE

